kwic
tumor
tumor
right
off
ON
126
1
100
500
strict
ELIZA cgi-bash version rev. 1.90
- Medical English LInking keywords finder for the PubMed Zipped Archive (ELIZA) -
return
kwic search for tumor out of >500 occurrences
305909 occurrences (No.73 in the rank) during 5 years in the PubMed. [no cache] 500 found
--- ABSTRACT ---
--- ABSTRACT END ---
[frequency of next (right) word to tumor]
305909 occurrences (No.73 in the rank) during 5 years in the PubMed. [no cache] 500 found
| 126) The treatments significantly inhibited tumor growth and reduced tumor weight and volume in the HL-60 xenograft mice. |
| PMID:24474168 DOI:10.1002/tox.21959 |
| 2015 Environmental toxicology |
| * Antitumor effects with apoptotic death in human promyelocytic leukemia HL-60 cells and suppression of leukemia xenograft tumor growth by irinotecan HCl. |
| - Irinotecan HCl (CPT-11) is an anticancer prodrug, but there is no available information addressing CPT-11-inhibited leukemia cells in in vitro and in vivo studies. Therefore, we investigated the cytotoxic effects of CPT-11 in promyelocytic leukemia HL-60 cells and in vivo and tumor growth in a leukemia xenograft model. Effects of CPT-11 on HL-60 cells were determined using flow cytometry, immunofluorescence staining, comet assay, real-time PCR, and Western blotting. CPT-11 demonstrated a dose- and time-dependent inhibition of cell growth, induction of apoptosis, and cell-cycle arrest at G0/G1 phase in HL-60 cells. CPT-11 promoted the release of AIF from mitochondria and its translocation to the nucleus. Bid, Bax, Apaf-1, caspase-9, AIF, Endo G, caspase-12, ATF-6b, Grp78, CDK2, Chk2, and cyclin D were all significantly upregulated and Bcl-2 was down-regulated by CPT-11 in HL-60 cells. Induction of cell-cycle arrest by CPT-11 was associated with changes in expression of key cell-cycle regulators such as CDK2, Chk2, and cyclin D in HL-60 cells. To test whether CPT-11 could augment antitumor activity in vivo, athymic BALB/c(nu/nu) nude mice were inoculated with HL-60 cells, followed by treatment with either CPT-11. The treatments significantly inhibited tumor growth and reduced tumor weight and volume in the HL-60 xenograft mice. The present study demonstrates the schedule-dependent antileukemia effect of CPT-11 using both in vitro and in vivo models. CPT-11 could potentially be a promising agent for the treatment of promyelocytic leukemia and requires further investigation. |
[
right
kwic]
(1)36  cells |
(17)6 size |
(33)3 lysis |
(49)2 progression, |
| (2)23 suppressor |
(18)6 suppression |
(34)3 onset |
(50)2 recurred |
| (3)22 progression |
(19)6 tissue |
(35)3 targeting |
(51)2 recurrence |
| (4)20 necrosis |
(20)6 with |
(36)3 to |
(52)2 regression |
| (5)19 *null* | (21)5 angiogenesis |
(37)3 types |
(53)2 response |
| (6)17 growth |
(22)5 initiating |
(38)2 1 |
(54)2 samples, |
| (7)15 cell |
(23)5 suppressive |
(39)2 activity |
(55)2 site |
| (8)14 was |
(24)5 volume |
(40)2 burden |
(56)2 size, |
| (9)12 and |
(25)4 model |
(41)2 classification |
(57)2 that |
| (10)11 development |
(26)4 sites |
(42)2 composed |
(58)2 the |
| (11)11 in |
(27)4 suppressors |
(43)2 expression |
(59)2 tissue, |
| (12)11 of |
(28)3 effects |
(44)2 heterogeneity |
(60)2 tissues |
| (13)7 microenvironment |
(29)3 excision |
(45)2 invasion |
(61)2 treatment |
| (14)6 formation |
(30)3 extension |
(46)2 is |
|
| (15)6 promotion |
(31)3 had |
(47)2 metastasis |
|
| (16)6 samples |
(32)3 local |
(48)2 mice |
add keyword
--- WordNet output for tumor ---